This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, Y. Articles by Nakano, H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, Y. Articles by Nakano, H.

Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer

Authors' Affiliations: Departments of ¹ Obstetrics and Gynecology, ² Neuropathology, ³ Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan and ⁴ Department of Cell Biology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Requests for reprints: Shingo Miyamoto, Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-5395; Fax: 81-92-642-5414; E-mail: smiya{at}med.kyushu-u.ac.jp.

Purpose: Lysophosphatidic acid, which is enriched in the peritoneal fluid of ovarian cancer patients, plays a key role in the progression of ovarian cancer. Lysophosphatidic acid can generate epidermal growth factor receptor (EGFR) signal transactivation involving processing of EGFR ligands by ADAM (a disintegrin and metalloprotease) family metalloproteases. We aimed to investigate the clinical significance of EGFR ligands and ADAM family in the lysophosphatidic acid–induced pathogenesis of ovarian cancer.

Experimental Design: We examined the expression of EGFR ligands and ADAM family members in 108 patients with normal ovaries or ovarian cancer, using real-time PCR, immunohistochemistry, and in situ hybridization, and analyzed the clinical roles of these molecules. Statistical analyses of these data were done using the Mann-Whitney test, Kaplan-Meier method, or Spearman's correlation analysis.

Results: Large differences in expression were found for heparin-binding EGF-like growth factor (HB-EGF) and other EGFR ligands and for ADAM 17 and other ADAM family members. HB-EGF expression was significantly increased in advanced ovarian cancer compared with that in normal ovaries (P < 0.01). HB-EGF expression was significantly associated with the clinical outcome (P < 0.01). ADAM 17 expression was significantly enhanced in both early and advanced ovarian cancer compared with that in normal ovaries (both P < 0.01), although it had no clinical significance in the progression-free survival. HB-EGF expression was significantly correlated with ADAM 17 expression ( = 0.437, P < 0.01).

Conclusions: Our findings suggest that HB-EGF and ADAM 17 contribute to the progression of ovarian cancer and that HB-EGF plays a pivotal role in the aggressive behavior of a tumor in ovarian cancer.

This article has been cited by other articles:

				S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, and F. YOTSUMOTO Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands Anticancer Res, March 1, 2009; 29(3): 823 - 830. [Abstract] [Full Text] [PDF]

				J. P. Edwards, X. Zhang, and D. M. Mosser The Expression of Heparin-Binding Epidermal Growth Factor-Like Growth Factor by Regulatory Macrophages J. Immunol., February 15, 2009; 182(4): 1929 - 1939. [Abstract] [Full Text] [PDF]

				J. Sarup, P. Jin, L. Turin, X. Bai, M. Beryt, C. Brdlik, J. N. Higaki, B. Jorgensen, F. W. Lau, P. Lindley, et al. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts Mol. Cancer Ther., October 1, 2008; 7(10): 3223 - 3236. [Abstract] [Full Text] [PDF]

				H. Yagi, F. Yotsumoto, and S. Miyamoto Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition Mol. Cancer Ther., October 1, 2008; 7(10): 3441 - 3451. [Abstract] [Full Text] [PDF]

				T. Kageyama, M. Ohishi, S. Miyamoto, H. Mizushima, R. Iwamoto, and E. Mekada Diphtheria Toxin Mutant CRM197 Possesses Weak EF2-ADP-ribosyl Activity that Potentiates its Anti-tumorigenic Activity J. Biochem., July 1, 2007; 142(1): 95 - 104. [Abstract] [Full Text] [PDF]

				P. M. McGowan, B. M. Ryan, A. D.K. Hill, E. McDermott, N. O'Higgins, and M. J. Duffy ADAM-17 Expression in Breast Cancer Correlates with Variables of Tumor Progression Clin. Cancer Res., April 15, 2007; 13(8): 2335 - 2343. [Abstract] [Full Text] [PDF]

				B. Santiago-Josefat, C. Esselens, J. J. Bech-Serra, and J. Arribas Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors J. Biol. Chem., March 16, 2007; 282(11): 8325 - 8331. [Abstract] [Full Text] [PDF]

				E. Nishi, Y. Hiraoka, K. Yoshida, K. Okawa, and T. Kita Nardilysin Enhances Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor through Activation of Tumor Necrosis Factor-{alpha}-converting Enzyme J. Biol. Chem., October 13, 2006; 281(41): 31164 - 31172. [Abstract] [Full Text] [PDF]